There is no biotech plant specialized in manufacturing of crystals in MENA region.
Total imports of insulin by MENA countries exceeded US$ 1 billion during the last six years (2002-2007) with imports reaching US$ 316 million in 2007, with a compound average growth rate (CAGR) estimated at 32%.
EBPF has been established for the purpose of constructing and operating a recombinant human insulin crystals plant of a nominal capacity design of 800 kg of recombinant human insulin crystals per year. The crystals will be processed further to produce about 20 millions vials of insulin per year.
The plant will have a multipurpose recombinant fermentation facility. These facilities will produce insulin crystals and ready insulin vials. The plant will possess the ability to stretch, and diversify its biotech portfolio to include -in addition to insulin- newer products that deal with some of the most vital needs of pharmaceutical markets in MENA region. Pipe- line products include Human Growth Hormone, Interferon Beta, Erythropoietin and Granulocyte Colony Stimulating Factor.